{"id":"W3031108451","doi":"10.1200/jco.2020.38.15_suppl.tps5090","title":"A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Bladder cancer; Internal medicine; Oncology; Tolerability; Mesylate; Immunotherapy; Cancer; Urology; Adverse effect","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001564674,0.001559863,0.001941392,0.0003453103,0.0004067987,0.001286748,0.0009730782,0.001793373,0.007416944],"category_scores_gemma":[0.001333444,0.0008005583,0.001463259,0.0003416943,0.001081617,0.001069478,0.0004137022,0.003492082,0.001501435],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008097034,"about_ca_system_score_gemma":0.001250585,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0011669,"about_ca_topic_score_gemma":0.003349237,"domain_scores_codex":[0.9996579,0.0001644637,0.0000160401,0.00007371056,0.00002285941,0.00006499613],"domain_scores_gemma":[0.9991655,0.000184343,0.000152996,0.00007581268,0.00004481509,0.0003766498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9627278,0.01980096,0.000672458,0.0003079066,0.0005765386,0.00003332152,0.00005111048,0.0002838777,0.003908981,0.0001077314,0.0009360418,0.01059321],"study_design_scores_gemma":[0.9130507,0.08313678,0.001632601,0.00001987823,0.0004116929,0.0000330389,0.00002718071,0.0004283402,0.000421213,0.000129599,0.0006942016,0.00001475469],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878896,0.002223155,0.0006102076,0.0007186116,0.0007253326,0.004229414,0.001328256,0.0001257951,0.002149665],"genre_scores_gemma":[0.9844636,0.001823288,0.001492318,0.001371976,0.0003738147,0.004043871,0.00162081,0.00003747658,0.004772869],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007416944,"threshold_uncertainty_score":0.0248121,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.114785495143352,"score_gpt":0.4457963786370255,"score_spread":0.3310108834936735,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}